Mergers and Acquisitions - Cixing Co., Ltd. plans to acquire 75% of Shenyang Shunyi Technology Co., Ltd. through a combination of issuing shares and cash payments, while also raising supporting funds from no more than 35 qualified investors [1] - United Optoelectronics intends to purchase 100% of Changyi Optoelectronics from 12 shareholders via share issuance and will also raise supporting funds [2] - Inte Group's subsidiary, Inte Pharmaceutical, successfully acquired 100% equity of Zhejiang Huadong Pharmaceutical Group Co., Ltd. for 369 million yuan and signed a transaction contract with the transferor [3] Shareholding Changes - Guokang Biochemical announced that shareholders plan to collectively reduce their holdings by no more than 6% of the company's total shares, with specific plans from two major shareholders to reduce by 3% each [4] - Ruilian New Materials reported that a major shareholder, Guofu Yongyu, plans to reduce its holdings by up to 3.33%, equivalent to 573,110 shares [5] - Hongxin Technology disclosed that two major shareholders, Baiqiang and Taizhou Qixin, plan to reduce their holdings by 2.62% and 2.12% respectively [6] Risk Matters - Sinovac Biotech highlighted the high-tech, high-risk, and high-value characteristics of its innovative drugs, emphasizing the uncertainties involved in the research and approval processes [7] - Zhongheng Design noted that the revenue from its low-altitude economy and commercial aerospace projects is minimal compared to its consolidated financial statements, despite winning several contracts in these sectors [8] Restructuring - *ST Xinyan announced that it received a notice from a creditor applying for the company's restructuring and pre-restructuring procedures [10]

3、公司目前的产能利用率如何？能否满足大客户的出货需 求？未来的产能规划如何？ 公司目前维持着较高的产能利用率。公司已增设专用产线， 积极配合大客户的出货需求。未来通过光学镜头及模组产能扩建 项目的实施，公司将新增年产逾 3,500 万颗精密光学镜头及摄像 模组的产能，能有效满足自身拓展不同应用领域市场的业务需求。 证券代码：301479 证券简称：弘景光电 广东弘景光电科技股份有限公司投资者关系活动记录表 编号：2025-005 投资者关系活动 类别 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 人员姓名 禾其投资杨硕梅今天 国泰君安国际 王彤 广发基金 马英皓冯骋陈少平 国泰海通证券刘晶晶 胡玮腾 文灿 时间 2025 年 6 月 3 日 地点 公司会议室（现场及电话会议） 公司接待人员 姓名 董事会秘书林琼芸女士 证券事务代表钟倩文女士 投资者关系活动 主要内容介绍 1、公司与影石合作的契机和历程。 2015 年，公司与影石创新开始接洽，当时双方都是处于成长 初期的创新型企业，基于全景影像的市场机遇和两家公司的互补 需求，双方达成了合 ...

Market Overview - The report provides a comprehensive analysis of the shipborne infrared night vision device market, including its current status and future trends from 2019 to 2031 [3][4] - The market is segmented by product type, including image intensifiers and thermal imaging devices, with growth trends projected for each category [3][4] Supply and Demand Analysis - Global supply and demand dynamics for shipborne infrared night vision devices are examined, highlighting production capacity, output, and utilization rates from 2019 to 2031 [4][5] - The report details China's production capacity and market demand, indicating its significant role in the global market [4][5] Regional Market Insights - The report analyzes the market size and revenue for major regions, including North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, comparing data from 2019, 2025, and 2031 [4][5][6] - Specific insights into the sales volume and revenue trends for each region are provided, showcasing the competitive landscape [4][5][6] Competitive Landscape - The competitive dynamics of the global market are assessed, identifying key manufacturers and their market shares in terms of production capacity, sales volume, and revenue from 2019 to 2025 [5][6] - The report ranks the top manufacturers by revenue for 2025, providing insights into their market positions [5][6] Product Type and Application Analysis - The report categorizes the market based on different product types and applications, detailing sales volume and revenue trends from 2019 to 2031 [5][6] - It highlights the growth potential in various applications, including cruise ships and cargo vessels [5][6] Industry Development Trends - The report discusses the overall development trends in the shipborne infrared night vision device industry, including driving factors and barriers to entry [6][7] - A SWOT analysis of Chinese enterprises in the industry is included, providing insights into their strengths, weaknesses, opportunities, and threats [6][7] Supply Chain and Procurement Analysis - An overview of the supply chain for the shipborne infrared night vision device industry is presented, including key raw materials and procurement models [6][7] - The report also examines the production and sales models prevalent in the industry [6][7]

证券研究报告 | 策略报告 gszqdatemark 2025 06 03 年 月 日 海外市场 扰动收敛，港股再启程——2025 年 6 月海外金股推荐 近期重点事件： 美国国际贸易法院裁定特朗普一揽子关税政策非法。5 月 12 日，中美双方发布《中 美日内瓦经贸会谈联合声明》，大幅减少双方此前加征的对等关税，中美之间关税 政策扰动就此告一段落。新华社北京 5 月 29 日电，位于纽约的美国国际贸易法院 28 日裁定特朗普政府一揽子关税政策非法，下令撤销其依据《国际紧急经济权力 法》推动的关税措施。特朗普政府已就此提起上诉。 关注 6 月中上旬的 CVPR。国际计算机视觉与模式识别会议（CVPR 2025）即将 于 2025 年 6 月 11 日至 15 日在美国田纳西州纳什维尔召开。CVPR 是全球计算机 视觉与人工智能领域最具影响力的顶级学术会议，汇聚了来自世界各地的专家学 者，共同探讨和分享最新的研究成果。 关注特斯拉 6 月 robotaxi 进展。特斯拉计划于 6 月 12 日在美国得克萨斯州奥斯 汀市推出全无人驾驶出租车服务 Robotaxi。该公司 CEO 马斯克此前确认，该服务 将率先在奥斯 ...

Core Insights - The report highlights the strong performance of China's innovative pharmaceuticals, particularly in international markets, with the MSCI China Healthcare Index rising 27.6% year-to-date, outperforming the MSCI China Index by 14.5% [2] - Significant overseas licensing deals for innovative drugs are being realized, showcasing the international competitiveness of Chinese pharmaceutical companies [6][7] - The report recommends several companies in the pharmaceutical sector, including BeiGene, Innovent Biologics, and others, as potential investment opportunities due to favorable market conditions [7] Industry Analysis - The innovative drug sector is benefiting from overseas licensing transactions, optimization of domestic procurement policies, and the implementation of new medical insurance directories, which are expected to drive valuation recovery in the pharmaceutical industry by 2025 [7] - The report notes that the recent updates from companies like Innovent Biologics and 3SBio at the ASCO conference demonstrate their clinical advancements and potential market impact [2][5] - The report anticipates continued growth in the domestic insurance market, with a projected 12.7% year-on-year increase in total premiums for the first four months of the year, indicating strong growth potential for internet insurance companies [10] Company Insights - 3SBio's licensing agreement with Pfizer for its PD-1/VEGF drug is expected to yield $1.25 billion in upfront payments and up to $4.8 billion in milestone payments, reflecting the drug's best-in-class potential [6] - The report highlights the positive outlook for ZhongAn Online due to its involvement in the stablecoin regulatory framework in Hong Kong, which is expected to enhance its valuation [8][9] - The report projects that ZhongAn's insurance premium growth will be driven by health and automotive sectors, with an expected combined ratio improvement due to better underwriting practices [10]

中经院表示，制造业的保守观望、股市回调所带来的负面财富效应、消费者信心低迷等，均影响经济走 势。连贤明分析，厂商目前虽未陷入悲观，但乐观情绪仍显不足，美国关税政策对制造业的影响有望于 6、7月间逐渐明朗。(完) 中经院介绍，5月PMI五项组成指标中，经季节调整后，新增订单与人力雇用仍处于紧缩，生产活动由 紧缩转为扩张，供货商交货时间延长，存货则持续增加。制造业六大产业中，电子暨光学、电力暨机械 设备、化学暨生技医疗三大产业呈现扩张，交通工具、基础原物料、食品暨纺织产业则仍呈现紧缩。 非制造业方面，中经院指出，5月未经季节调整的台湾非制造业采购经理人指数(NMI)已连续3个月扩 张，本月NMI微升0.9个百分点至51.9%。非制造业商业活动与新增订单指数同步转为扩张，但未来展望 指数连续第三个月呈现紧缩。 中新社台北6月2日电 (记者张晓曦)台湾中华经济研究院(简称"中经院")2日在台北公布，经季节调整后， 今年5月台湾制造业采购经理人指数(PMI)回升2.1个百分点至51%，与4月相比由紧缩转为扩张。中经院 院长连贤明指出，厂商决策仍偏保守，目前"谈不上乐观"。 PMI高于50%表示景气处于扩张期，低于50% ...

以下文章来源于睿兽Pro ，作者Bestla 睿兽Pro . 创业邦旗下横跨一二级市场的科创数据平台。实时投资数据、追踪产业创新。找数据、做分析、链资 源，就上睿兽分析。 截至 2025年3月31日，全国专精特新小巨人企业超1.4万家。 其中江苏以 2160家领先全国，广东 1985家位居第二位，浙江1804家、山东1162家、北京1036家分别位列第三至第五位。 一级市场趋冷，小巨人融资事件及金额均下降五成左右。 2025Q1，专精特新小巨人企业一级市场发 生融资事件136起，同比下降55.0%，已披露融资金额98.5亿元，同比下降48.1%。 IPO减缓，但A股新增IPO中小巨人占比提升。 2025Q1，19家专精特新小巨人企业IPO，同比增长 26.7%； A股新增27家IPO企业中，专精特新小巨人企业18家，占比66.7%，较2024Q4（74.2%） 下降7.5个百分点。 并购活跃，小巨人企业成为并购热门标的。 2025Q1披露以专精特新小巨人企业为标的的并购事件 29起，同比增长262.5%；已披露交易金额共51.6亿元，同比增长26.8%。 小巨人企业发展概况 专精特新小巨人企业总量超 1.4万 ...

Summary of Key Points Core Viewpoint - The report provides an overview of the fundraising activities and the usage of funds by Jiangxi Woge Optoelectronics Group Co., Ltd. as of March 31, 2025, confirming compliance with regulatory requirements and reflecting the actual usage of previously raised funds [1][3]. Fundraising and Storage - The company raised a total of RMB 170.50 million through a non-public offering of 14,800,347 shares at RMB 11.52 per share, with net proceeds amounting to RMB 166.77 million after deducting underwriting and sponsorship fees [3][4]. - As of March 31, 2025, the total amount of funds stored in the bank account was RMB 167.70 million, with a noted difference of RMB 1.58 million due to deducted fees [5][6]. Fund Usage - The actual investment amount from the raised funds was RMB 166.13 million, which is RMB 1.53 million more than the committed investment amount, attributed to interest income and net fees [6][7]. - The funds were primarily used to supplement working capital and repay bank loans, enhancing the company's operational capacity and risk management, but did not generate direct measurable benefits [6][7]. Fund Management - There were no instances of idle funds being used for cash management as of the reporting date [7]. - The company did not engage in any transfer or replacement of investment projects funded by the previous fundraising [6][7].

其中，"海外智能制造产业基地扩建项目"在推进过程中，国际贸易环境发生较大变化，贸易政策频繁更迭，地缘政治冲突进一步加剧，为降低投资风险，同 时满足客户扩建产能快速落地需求，光莆股份拟使用募集资金先租赁厂房并进行装修，快速实现部分产能的投产，满足市场和客户的即时需求，降低前期资 金投入压力与投资风险；后续待国际贸易形势趋于明朗、贸易政策趋于稳定后，再继续推进海外购地和厂房建设。 基于此，光莆股份经审慎研究后决定增加该募投项目的实施方式：租赁厂房和厂房装修，并将该项目达到预定可使用状态日期延长至2027年12月31日。 光莆股份于2020年9月非公开发行不超过71,363,368股新股，共计募集人民币1,030,803,595.51元。扣除与发行有关的费用，实际募集资金净额为人民币 1,017,663,459.71元。 光莆股份于2024年7月审议通过了《关于变更部分募集资金用途及新增募集资金投资项目的议案》，同意公司将"高光功率紫外固态光源产品建设项 目"和"LED照明产品智能化生产建设项目"尚未使用的募集资金及累计收益用于实施公司新增的募投项目"光电传感器件集成封测研发及产业化项目"和"海外 智能制造产业基地 ...

Core Viewpoint - The company has completed the main renovation of its micro-nano optical laboratory and has introduced some experimental equipment, focusing on the development of sub-wavelength structured optical components [1] Group 1: Company Developments - The company is engaged in the research and development of sub-wavelength structured optical components, including superlenses and metasurface devices [1] - The application scenarios for these developments include semiconductor optics, photovoltaics and new energy, AR/VR, and infrared fields [1]